Mesalazine-induced apoptosis of colorectal cancer: On the verge of a new chemopreventive era?

Alimentary Pharmacology and Therapeutics

Volumn 13, Issue 11, 1999, Pages 1397-1402

  Bus, P J ^a   Nagtegaal, I D ^a   Verspaget, H W ^a   Lamers, C B H W ^a   Geldof, H ^a,b   Van Krieken, J H J M ^a   Griffioen, G ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^b IJSSELLAND HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ENEMA; EOSIN; HEMATOXYLIN; KI 67 ANTIGEN; MESALAZINE;

ADULT; AGED; APOPTOSIS; ARTICLE; CANCER PREVENTION; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFECT; DRUG SAFETY; DRUG SELECTIVITY; FEMALE; HUMAN; HUMAN CELL; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RECTAL DRUG ADMINISTRATION; TUMOR BIOPSY; TUMOR CELL;

AGED; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; APOPTOSIS; BIOLOGICAL MARKERS; CELL DIVISION; CELLS, CULTURED; COLONOSCOPY; COLORECTAL NEOPLASMS; ENEMA; FEMALE; HUMANS; INTESTINAL MUCOSA; KI-67 ANTIGEN; MALE; MESALAMINE; MIDDLE AGED; PILOT PROJECTS; PROSPECTIVE STUDIES;

EID: 0032720159     PISSN: 02692813     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2036.1999.00652.x     Document Type: Article

References (34)

1. 1 Shiff SJ, Koutsos MI, Qiao L, Rigas B. Nonsteroidal anti-inflammatory drugs inhibit the proliferation of colon adenocarcinoma cells: effects on cell cycle and apoptosis. Exp Cell Res 1996; 222: 179-88.
2. 2 Elder DJE, Hague A, Hicks DJ, Paraskeva C. Differential growth inhibition by the aspirin metabolite salicylate in human colorectal tumor cell lines: enhanced apoptosis in carcinoma and in vitro-transformed adenoma relative to adenoma cell lines. Cancer Res 1996; 56: 2273-6.
3. 3 Rao CV, Rivenson A, Simi B, et al. Chemoprevention of colon carcinogenesis by Sulindac, a nonsteroidal anti-inflammatory agent. Cancer Res 1995; 55: 1464-72.
4. 4 Thun MJ, Namboodiri MM, Heath CW. Aspirin use and reduced risk of fatal colon cancer. N Engl J Med 1991; 325: 1593-6.
5. 5 Thun MJ, Namboodiri MM, Calle EE, Flanders WD, Heath CW. Aspirin use and risk of fatal cancer. Cancer Res 1993; 53: 1322-7.
6. 6 Giovannucci E, Rimm EB, Stampfer MJ, Colditz GA, Ascherio A, Willett WC. Aspirin use and the risk for colorectal cancer and adenoma in male health professionals. Ann Intern Med 1994; 121: 241-6.
7. 7 Peleg II, Maibach HT, Brown SH, Wilcox CM. Aspirin and nonsteroidal anti-inflammatory drug use and the risk of subsequent colorectal cancer. Arch Intern Med 1994; 154: 394-9.
8. 8 Giovannucci E. Egan KM, Hunter DJ, et al. Aspirin and the risk of colorectal cancer in women. N Engl J Med 1995; 333: 609-14.
9. 9 Smalley W, Ray WA, Daugherty J, Griffin MR. Use of nonsteroidal anti-inflammatory drugs and incidence of colorectal cancer. Arch Intern Med 1999; 159: 161-6.
10. 10 Waddell WR, Ganser GF, Cerise EJ, Loughry RW. Sulindac for polyposis of the colon. Am J Surg 1989; 157: 175-9.
11. 11 Sandler RS, Galanko JC, Murray SC, Helm JF, Woosley JT. Aspirin and nonsteroidal anti-inflammatory agents and risk for colorectal adenomas. Gastroenterology 1998; 114: 441-7.
12. 12 Giardiello FM, Hamilton SR, Krush AJ, et al. Treatment of colonic and rectal adenomas with sulindac in familial adenomatous polyposis. N Engl J Med 1993; 328: 1313-16.
13. 13 Giardiello FM, Offerhaus JA, Tersmette AC, et al. Sulindac induced regression of colorectal adenomas in familial adenomatous polyposis: evaluation of predictive factors. Gut 1996; 38: 578-81.
14. 14 Matsuhashi N, Nakajima A, Fukushima Y, Yazaki Y, Oka T. Effects of sulindac on sporadic colorectal adenomatous polyps. Gut 1997; 40: 344-9.
15. 15 Pasricha PJ, Bedi A, O'Connor K, et al. The effects of sulindac on colorectal proliferation and apoptosis in familial adenomatous polyposis. Gastroenterology 1995; 109: 994-8.
16. 16 Fearon ER, Vogelstein B. A genetic model for colorectal tumorigenesis. Cell 1990; 61: 759-67.
17. 17 Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for the aspirin-like drugs. Nature 1971; 231: 232-5.
18. 18 Eberhart CE, Coffey RJ, Radhika A, Giardiello FM, Ferrenbach S, Dubois RN. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterology 1994; 107: 1183-8.
19. 19 Clive DM, Stoff JS. Renal syndromes associated with nonsteroidal anti-inflammatory drugs. N Engl J Med 1984; 310: 563-72.
20. 20 Silagy CA, McNeil JJ, Donnan GA, Tonkin AM, Worsam B, Campion K. Adverse effects of low-dose aspirin in a healthy elderly population. Clin Pharmacol Ther 1993; 54: 84-9.
21. 21 Weil J, Colin-Jones D, Langman M, et al. Prophylactic aspirin and risk of peptic ulcer bleeding. Br Med J 1995; 310: 827-30.
22. 22 Bjarnason I, Macpherson AJ. Delivery, safety and efficacy of 5-aminosalicylate preparations. Inflammopharmacology 1993; 2: 277-87.
23. 23 Ireland A, Jewell DP. Mechanism of action of 5-aminosalicylic acid and its derivatives. Clin Sci 1990; 78: 119-25.
24. 24 Samaha HS, Kelloff GJ, Steele V, Rao CV, Reddy BS. Modulation of apoptosis by sulindac, curcumin, phenylethyl-3-methylcaffeate, and 6-phenylhexyl isothiocyanate: apoptotic index as a biomarker in colon cancer chemoprevention and promotion. Cancer Res 1997; 57: 1301-5.
25. 25 Potten CS. The significance of spontaneous and induced apoptosis in the gastrointestinal tract of mice. Cancer Metastasis Rev 1992; 11: 179-95.
26. 26 Clahsen PC, van de Velde CJH, Duval C. et al. p53 protein accumulation and response to adjuvant chemotherapy in premenopausal women with node-negative early breast cancer. J Clin Oncol 1998; 16: 470-9.
27. 27 Pollard M, Luckert PH. Effect of indomethacin on intestinal tumors induced in rats by the acetate derivative of dimethylnitrosamine. Science 1981; 214: 558-9.
28. 28 Rubio CA, Wallin B, Ware J, Sveander M, Duvander A. Effect of indomethacin in autotransplanted colonic tumors. Dis Colon Rectum 1989; 32: 488-91.
29. 29 Winde G, Schmid KW, Schlegel W, Fisher R, Osswalt H, Bünte H. Complete reversion and prevention of rectal adenomas in colectomixed patients with familial adenomatous polyposis by rectal low-dose sulindac maintenance treatment. Dis Colon Rectum 1995; 38: 813-30.
30. 30 Aoki T, Boland CR, Brenner DE. Aspirin modulation of pre-malignant biomarkers in rectal mucosa of high-risk subjects. Gastroenterology 1996; 110: A484(Abstract).
31. 31 Spagnesi MT, Tonelli F, Dolara P, et al. Rectal proliferation and polyp occurrence in patients with familial adenomatous polyposis after sulindac treatment. Gastroenterology 1994; 106: 362-6.
32. 32 Piazza GA, Rahm AK, Finn TS, et al. Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res 1997; 57: 2452-9.
33. 33 Chan TA, Morin PJ, Vogelstein B, Kinzler KW. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc Natl Acad Sci USA 1998; 95: 681-6.
34. 34 Rioux N, Castonguay A. Inhibitors of lipoxygenase: a new class of cancer chemopreventive agents. Carcinogenesis 1998; 19: 1393-400.